ShengJing Hospital of China Medical University (China Medical University No.2 Ho spital )
🇨🇳China
Clinical Study on the Efficacy and Safety of Qingre Heji in the Treatment of Acute Upper Respiratory Tract Infection
Phase 1
Completed
- Conditions
- Acute Upper Respiratory Tract InfectionRandomised Controlled TrialTraditional Chinese Medicine
- Interventions
- Drug: Qing Re He Ji
- First Posted Date
- 2024-07-25
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- Shengjing Hospital
- Target Recruit Count
- 268
- Registration Number
- NCT06520618
- Locations
- 🇨🇳
Shengjing Hospital of China Medical University, Shenyang, Liaoning, China
A Joint Model Based on Deep Learning to Predict Multidrug-resistant Klebsiella Pneumoniae Liver Abscess
Recruiting
- Conditions
- Liver Abscess
- First Posted Date
- 2024-07-17
- Last Posted Date
- 2024-07-17
- Lead Sponsor
- Shengjing Hospital
- Target Recruit Count
- 550
- Registration Number
- NCT06506318
- Locations
- 🇨🇳
Shengjing hospital of China medical university, Shenyang, Liaoning, China
Prediction and Prognostic Analysis of Liver Abscess Formation After Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma (CHANCE 2407)
Not yet recruiting
- Conditions
- Liver AbscessTACEHCC - Hepatocellular Carcinoma
- First Posted Date
- 2024-07-03
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Shengjing Hospital
- Target Recruit Count
- 400
- Registration Number
- NCT06483594
Multi-parametric Magnetic Resonance Imaging for the Precise Diagnosis and Quantitative Study of Liver Steatosis, Inflammation, and Fibrosis in Chronic Liver Disease.
Recruiting
- Conditions
- Liver Stiffness
- First Posted Date
- 2024-06-17
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- Shengjing Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT06463366
- Locations
- 🇨🇳
Shengjing Hospital of China Medical University, Shenyang, Liaoning, China
Multimodal Magnetic Resonance Imaging in Evaluation of Diabetic Kidney Disease
Recruiting
- Conditions
- Diabetic Kidney Disease
- First Posted Date
- 2024-06-11
- Last Posted Date
- 2024-06-11
- Lead Sponsor
- Shengjing Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT06452862
- Locations
- 🇨🇳
Shengjing Hospital, Shenyang, Liaoning, China
SHR-A1811 Alone or in Combination With Adebrelimab as Neoadjuvant Treatment in HR Positive/HER2 Low Breast Cancer
Phase 2
Recruiting
- Conditions
- HR Positive/HER2 Low Breast Cancer
- Interventions
- Drug: SHR-A1811 InjectionDrug: SHR-A1811 Injection + Adebrelimab Injection
- First Posted Date
- 2024-04-01
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Shengjing Hospital
- Target Recruit Count
- 93
- Registration Number
- NCT06340230
- Locations
- 🇨🇳
Shengjing Hospital affiliated to China Medical University, Shenyang, Liaoning, China
Clinical Study of High-intensity Focused Ultrasound Tumor Treatment System(Super Knife) in the Treatment of Breast Cancer
Not Applicable
Recruiting
- Conditions
- Breast Cancer
- First Posted Date
- 2024-01-18
- Last Posted Date
- 2024-01-18
- Lead Sponsor
- Shengjing Hospital
- Target Recruit Count
- 12
- Registration Number
- NCT06210529
- Locations
- 🇨🇳
Shengjing Hospital of China Medical University, Shenyang, Liaoning, China
MRE for Assessment of Histopathological Growth Patterns in Colorectal Liver Metastases
Recruiting
- Conditions
- Metastatic Colorectal Cancer
- First Posted Date
- 2024-01-17
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Shengjing Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT06208397
- Locations
- 🇨🇳
Shengjing Hospital of China Medical University, Shenyang, Liaoning, China
3D-MRE and 2D-MRE for Assessing Cirrhosis and Portal Hypertension
Recruiting
- Conditions
- CirrhosisLiver Portal Hypertension
- First Posted Date
- 2024-01-16
- Last Posted Date
- 2025-02-26
- Lead Sponsor
- Shengjing Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT06205992
- Locations
- 🇨🇳
Shengjing Hospital of China Medical University, Shenyang, Liaoning, China
Study of Cadonilimab (AK104) Plus Eribulin vs. Eribulin Monotherapy for Recurrent or Metastatic Triple-negative Breast Cancer
Phase 2
Not yet recruiting
- Conditions
- Triple Negative Breast Cancer
- Interventions
- Biological: Cadonilimab
- First Posted Date
- 2024-01-11
- Last Posted Date
- 2024-01-11
- Lead Sponsor
- Shengjing Hospital
- Target Recruit Count
- 128
- Registration Number
- NCT06202313
- Locations
- 🇨🇳
Shengjing Hospital of China Medical University, Shenyang, Liaoning, China